- Home
- WLY vs GH Comparison
WLY vs GH Comparison
Compare WLY & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- GH
- Stock Information
- Founded
- WLY 1807
- GH 2011
- Country
- WLY United States
- GH United States
- Employees
- WLY N/A
- GH N/A
- Industry
- WLY Books
- GH Medical Specialities
- Sector
- WLY Consumer Discretionary
- GH Health Care
- Exchange
- WLY Nasdaq
- GH Nasdaq
- Market Cap
- WLY 2.7B
- GH 4.3B
- IPO Year
- WLY N/A
- GH 2018
- Fundamental
- Price
- WLY $42.38
- GH $37.46
- Analyst Decision
- WLY
- GH Strong Buy
- Analyst Count
- WLY 0
- GH 14
- Target Price
- WLY N/A
- GH $39.93
- AVG Volume (30 Days)
- WLY 423.1K
- GH 1.8M
- Earning Date
- WLY 03-06-2025
- GH 02-20-2025
- Dividend Yield
- WLY 3.36%
- GH N/A
- EPS Growth
- WLY N/A
- GH N/A
- EPS
- WLY N/A
- GH N/A
- Revenue
- WLY $1,759,570,000.00
- GH $692,256,000.00
- Revenue This Year
- WLY N/A
- GH $32.21
- Revenue Next Year
- WLY $1.13
- GH $16.90
- P/E Ratio
- WLY N/A
- GH N/A
- Revenue Growth
- WLY N/A
- GH 29.20
- 52 Week Low
- WLY $31.87
- GH $15.81
- 52 Week High
- WLY $53.96
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- WLY 29.96
- GH 66.67
- Support Level
- WLY $41.48
- GH $34.80
- Resistance Level
- WLY $42.81
- GH $37.46
- Average True Range (ATR)
- WLY 0.91
- GH 1.78
- MACD
- WLY 0.03
- GH 0.51
- Stochastic Oscillator
- WLY 23.80
- GH 80.49
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.